This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Clemson University. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Christopher Fernandez: Innovator in Biomaterials
Introduction
Christopher Fernandez is an accomplished inventor based in Clifton, NJ (US). He has made significant contributions to the field of biomaterials, particularly in the development of decellularized tissues for medical applications. His innovative work focuses on creating materials that can be used as grafts or scaffolds in regenerative medicine.
Latest Patents
Fernandez holds a patent for a decellularized biomaterial and method for formation. This patent describes methods for developing decellularized tissue and biomaterials that are particularly well suited for use as intervertebral disc grafts. The decellularized tissue is derived from intervertebral disc source tissue and is designed to be substantially free of potential immunogenic material, such as DNA and RNA, while preserving essential extracellular matrix materials, including glycosaminoglycan and collagen.
Career Highlights
Christopher Fernandez is affiliated with Clemson University, where he continues to advance research in biomaterials. His work has the potential to significantly impact the field of tissue engineering and regenerative medicine. With a focus on creating effective and biocompatible materials, Fernandez is paving the way for innovative solutions in medical treatments.
Collaborations
One of his notable collaborators is Jeremy J Mercuri. Their partnership exemplifies the collaborative spirit in research, which often leads to groundbreaking advancements in technology and medicine.
Conclusion
Christopher Fernandez is a notable inventor whose work in decellularized biomaterials is shaping the future of regenerative medicine. His contributions are essential for developing effective treatments and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
